Physician profile
Mark A White
NPI 1134104706
$5,315.93
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $437 · 2020: $445 · 2021: $1,559 · 2022: $982 · 2023: $1,369 · 2024: $525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,894.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,893.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,456.91 | 2021-2024 | Ubrelvy, Qulipta, Vraylar |
| Glaxosmithkline, LLC. | $608.87 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $427.00 | 2019-2023 | Farxiga, Breztri |
| Amgen INC. | $319.90 | 2019-2023 | Prolia, Evenity, Otezla |
| Exact Sciences Corporation | $235.62 | 2023-2024 | Cologuard Collection Kit |
| Pfizer INC. | $177.08 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $163.12 | 2021-2023 | |
| Lilly USA, LLC | $142.85 | 2019-2024 | Jardiance, Mounjaro |
| Horizon Therapeutics Plc | $139.17 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $133.00 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $129.61 | 2022 | |
| Medtronic, INC. | $128.60 | 2021 | |
| Sunovion Pharmaceuticals INC. | $124.59 | 2019 | |
| Gilead Sciences, INC. | $120.18 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $115.22 | 2019-2023 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.